As of 2025-03-19, the EV/EBITDA ratio of Sigilon Therapeutics, Inc. (SGTX) is -0.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGTX's latest enterprise value is 32.33 mil USD. SGTX's TTM EBITDA according to its financial statements is -34.77 mil USD. Dividing these 2 quantities gives us the above SGTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 13.3x | 12.2x |
| Forward P/E multiples | 17.5x - 35.3x | 21.9x |
| Fair Price | (231.78) - (174.55) | (226.12) |
| Upside | -1131.5% - -876.8% | -1106.3% |
| Date | EV/EBITDA |